161 related articles for article (PubMed ID: 23940574)
1. Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.
Bowden NA; Ashton KA; Vilain RE; Avery-Kiejda KA; Davey RJ; Murray HC; Budden T; Braye SG; Zhang XD; Hersey P; Scott RJ
PLoS One; 2013; 8(8):e70424. PubMed ID: 23940574
[TBL] [Abstract][Full Text] [Related]
2. Nucleotide excision repair gene expression after Cisplatin treatment in melanoma.
Bowden NA; Ashton KA; Avery-Kiejda KA; Zhang XD; Hersey P; Scott RJ
Cancer Res; 2010 Oct; 70(20):7918-26. PubMed ID: 20807809
[TBL] [Abstract][Full Text] [Related]
3. Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair.
Budden T; Davey RJ; Vilain RE; Ashton KA; Braye SG; Beveridge NJ; Bowden NA
Oncotarget; 2016 Sep; 7(38):60940-60953. PubMed ID: 27487145
[TBL] [Abstract][Full Text] [Related]
4. DNA REPAIR. Drugging DNA repair.
Jackson SP; Helleday T
Science; 2016 Jun; 352(6290):1178-9. PubMed ID: 27257245
[No Abstract] [Full Text] [Related]
5. The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment.
Colton SL; Xu XS; Wang YA; Wang G
J Biol Chem; 2006 Sep; 281(37):27117-25. PubMed ID: 16849332
[TBL] [Abstract][Full Text] [Related]
6. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
[TBL] [Abstract][Full Text] [Related]
7. Triptolide induced DNA damage in A375.S2 human malignant melanoma cells is mediated via reduction of DNA repair genes.
Chueh FS; Chen YL; Hsu SC; Yang JS; Hsueh SC; Ji BC; Lu HF; Chung JG
Oncol Rep; 2013 Feb; 29(2):613-8. PubMed ID: 23233170
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
9. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization connects individual patient mutations in ataxia telangiectasia mutated (ATM) with dysfunction of specific DNA double-strand break-repair signaling pathways.
Keimling M; Volcic M; Csernok A; Wieland B; Dörk T; Wiesmüller L
FASEB J; 2011 Nov; 25(11):3849-60. PubMed ID: 21778326
[TBL] [Abstract][Full Text] [Related]
11. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB
Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541
[TBL] [Abstract][Full Text] [Related]
12. RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia.
Xu Y; Lin Y; Luo Y; Yang Y; Long B; Fang Z; Liu L; Zhang J; Zhang X
Oncol Rep; 2020 Oct; 44(4):1455-1466. PubMed ID: 32945515
[TBL] [Abstract][Full Text] [Related]
13. Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
Stok C; Kok YP; van den Tempel N; van Vugt MATM
Nucleic Acids Res; 2021 May; 49(8):4239-4257. PubMed ID: 33744950
[TBL] [Abstract][Full Text] [Related]
14. Functional profiling of nucleotide Excision repair in breast cancer.
Rajkumar-Calkins AS; Szalat R; Dreze M; Khan I; Frazier Z; Reznichenkov E; Schnorenberg MR; Tsai YF; Nguyen H; Kochupurakkal B; D'Andrea AD; Shapiro GI; Lazaro JB; Mouw KW
DNA Repair (Amst); 2019 Oct; 82():102697. PubMed ID: 31499327
[TBL] [Abstract][Full Text] [Related]
15. Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.
Budden T; van der Westhuizen A; Bowden NA
BMC Cancer; 2018 Jan; 18(1):100. PubMed ID: 29373959
[TBL] [Abstract][Full Text] [Related]
16. Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair.
Barckhausen C; Roos WP; Naumann SC; Kaina B
Oncogene; 2014 Apr; 33(15):1964-74. PubMed ID: 23604128
[TBL] [Abstract][Full Text] [Related]
17. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors.
Honrado E; Osorio A; Palacios J; Milne RL; Sánchez L; Díez O; Cazorla A; Syrjakoski K; Huntsman D; Heikkilä P; Lerma E; Kallioniemi A; Rivas C; Foulkes WD; Nevanlinna H; Benítez J
J Clin Oncol; 2005 Oct; 23(30):7503-11. PubMed ID: 16234517
[TBL] [Abstract][Full Text] [Related]
19. Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways.
Garcia K; Blank JL; Bouck DC; Liu XJ; Sappal DS; Hather G; Cosmopoulos K; Thomas MP; Kuranda M; Pickard MD; Liu R; Bandi S; Smith PG; Lightcap ES
Mol Cancer Ther; 2014 Jun; 13(6):1625-35. PubMed ID: 24672057
[TBL] [Abstract][Full Text] [Related]
20. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
